Compare General Dynamics Corporation (GD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? General Dynamics Corporation trades at $331.27 (market cap $89.26B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: General Dynamics Corporation is far larger — about 8.8× State Street SPDR S&P Biotech ETF's market cap, and General Dynamics Corporation pays a 1.93% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GD | XBI | |
|---|---|---|
Market Cap | $89.26B | $10.11B |
Volume | 1,496,273 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $395.97 | $169.55 |
52-Week Low | $312.53 | $104.99 |
Typical Hold Time | 85 Days | 38 Days |
Enterprise Value | $94.40B | — |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $329.90, up 1.0% with strong fundamental performance including three consecutive quarterly earnings beats and robust 2025 revenue of $52.55 billion. The stock shows bearish technical signals despite positive analyst sentiment with a $420.57 consensus price target representing 27.5% upside potential. Defense sector tailwinds from Pentagon spending and dividend stability support the investment case.
GD presents a compelling value opportunity with reasonable valuation multiples (P/E 20.12, P/S 1.65) and strong profitability metrics (ROE 17.8%, net margin 8.18%). Key risks include defense budget volatility and technical weakness, but the company's consistent earnings performance and analyst support suggest potential for medium-term appreciation.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
